abstract |
(a) a pharmaceutical combination comprising a B-Raf inhibitor, (b) an EGFR inhibitor, and optionally (c) a PI3K inhibitor; The use of such a combination in the treatment of proliferative disorders; And a method of treating a subject suffering from a proliferative disease, comprising administering a therapeutically effective amount of such a combination. |